NCT04592237 - Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaMetastatic Prostate Neuroendocrine CarcinomaMetastatic Prostate Small Cell CarcinomaStage IV Prostate Cancer AJCC v8

Interventions

DRUG

Cabazitaxel

Given IV

DRUG

Carboplatin

Given IV

BIOLOGICAL

Cetrelimab

Given IV

DRUG

Niraparib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston